Navigation Links
Poxvirus potency uncovered in new atomic map
Date:2/1/2008

BIRMINGHAM, Ala. Scientists at the University of Alabama at Birmingham (UAB) and Saint Louis University used X-ray crystallography to uncover new details about the infectious potency of poxviruses, furthering the understanding of how one protein in viral infections can subvert the bodys immune system.

Having high-resolution detail of this protein on hand will speed the discovery of new drugs to combat inflammation and immune diseases such as atherosclerosis and rheumatoid arthritis, the researchers said.

The findings are published in the online edition of journal Proceedings of the National Academy of Sciences and will soon appear in a print edition.

Now we have a visual blueprint to guide our future studies on interferon-gamma binding protein, which one day may be used to prevent inflammatory disease, said Mark R. Walter, Ph.D., an associate professor in the UAB Department of Microbiology and senior author on the study.

Interferon-gamma binding protein (IFN-y) is notorious for the role it plays in helping poxviruses replicate. Normally when a virus enters the bloodstream, the immune system fights back by producing IFN-y, which tells surrounding cells to fight the infection.

Remarkably, somewhere during the evolution of the poxvirus, it captured an IFN-y gene from its host and incorporated some of the protein structure into its own. As a result poxvirus has a very efficient blocker of the IFN-y antiviral response, Walter said.

The new study shows this blocking ability through crystallography, the science of mapping the atomic structure of molecules by looking at their interaction with an X-ray beam.

Poxviruses include many classes of the invasive organism such as smallpox, cowpox and monkeypox. Smallpox in particular has played a tragic role in human history: estimates show it caused between 300 million and 500 million deaths in the 20th Century.

Smallpox was declared officially eradicated in 1979, but other poxviruses remain a health threat.

The damage that the smallpox virus has done to mankind is horrific and enormous, which is why we think its so important to understand more about the poxviruses and how they operate, said Mark Buller, Ph.D., professor of microbiology and immunology at the Saint Louis University School of Medicine and a study author. The more knowledge we have, the better we should be able to cope with other major viruses and diseases in the future.


'/>"/>

Contact: Troy Goodman
tdgoodman@uab.edu
205-934-8938
University of Alabama at Birmingham
Source:Eurekalert

Related biology news :

1. Agent that triggers immune response in plants is uncovered
2. Hemoglobin uncovered
3. Anthrax cellular entry point uncovered
4. Scientists retrace evolution with first atomic structure of an ancient protein
5. Atomic bomb survivor, scientists mark 60 years of long-term radiation study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2016)... 2, 2016   The Weather Company , an IBM ... an industry-first capability in which consumers will be able to ... ask questions via voice or text and receive relevant information ... Marketers have long sought an advertising solution that ... be personal, relevant and valuable; and can scale across millions ...
(Date:5/24/2016)... 2016 Ampronix facilitates superior patient care by providing unparalleled technology to leaders ... is the latest premium product recently added to the range of products distributed by ... ... ... LCD Medical Display- Ampronix News ...
(Date:5/12/2016)... WearablesResearch.com , a brand of Troubadour ... from the Q1 wave of its quarterly wearables survey. ... receptivity to a program where they would receive discounts ... company. "We were surprised to see that ... LaColla , CEO of Troubadour Research, "primarily because there ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... OTTAWA, ON (PRWEB) , ... June 23, 2016 , ... ... former DNA Technical Leader at the Arkansas State Crime Laboratory, has joined STACS DNA ... joining the STACS DNA team,” said Jocelyn Tremblay, President and COO of STACS DNA. ...
(Date:6/23/2016)... , June 23, 2016 Apellis Pharmaceuticals, ... 1 clinical trials of its complement C3 inhibitor, ... and multiple ascending dose studies designed to assess ... of subcutaneous injection in healthy adult volunteers. ... either as a single dose (ranging from 45 ...
(Date:6/23/2016)... June 23, 2016 ... 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 Published recently ... peer-reviewed journal from touchONCOLOGY, Andrew D Zelenetz ... of cancer care is placing an increasing burden ... expensive biologic therapies. With the patents on many ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, ... Pennsylvania Convention Center and will showcase its product’s latest features from June 26 ... presenting a scientific poster on Disrupting Clinical Trials in The Cloud during the ...
Breaking Biology Technology: